Stabilized coronavirus spike protein fusion proteins
AssigneeJanssen Pharmaceuticals, Inc.
InventorsJaroslaw JURASZEK, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN
Life of this patent
Estimating the term…
Abstract
The present invention provides stabilized recombinant pre-fusion SARS COV-2 S proteins, nucleic acids molecules encoding the SARS-COV-2 S proteins and uses thereof.
Claims32
Recombinant pre-fusion SARS-COV-2 S protein, or a fragment thereof, comprising an S1 and an S2 domain, and comprising at least one mutation selected from the group consisting of a mutation of at least one amino acid in the loop region corresponding to amino acid residues 941-945 into P, a mutation of the amino acid at position 892, a mutation of the amino acid at position 614, a mutation at position 572, a mutation at position 532, a disulfide bridge between residues 880 and 888, and a disulfide bridge between residues 884 and 893, wherein the numbering of the amino acid positions is according to the numbering of the amino acid positions in SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.